Drevin, G.; Briet, M.; Bazzoli, C.; Gyan, E.; Schmidt, A.; Dombret, H.; Orvain, C.; Giltat, A.; Recher, C.; Ifrah, N.;
et al. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics 2022, 14, 792.
https://doi.org/10.3390/pharmaceutics14040792
AMA Style
Drevin G, Briet M, Bazzoli C, Gyan E, Schmidt A, Dombret H, Orvain C, Giltat A, Recher C, Ifrah N,
et al. Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics. 2022; 14(4):792.
https://doi.org/10.3390/pharmaceutics14040792
Chicago/Turabian Style
Drevin, Guillaume, Marie Briet, Caroline Bazzoli, Emmanuel Gyan, Aline Schmidt, Hervé Dombret, Corentin Orvain, Aurelien Giltat, Christian Recher, Norbert Ifrah,
and et al. 2022. "Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial" Pharmaceutics 14, no. 4: 792.
https://doi.org/10.3390/pharmaceutics14040792
APA Style
Drevin, G., Briet, M., Bazzoli, C., Gyan, E., Schmidt, A., Dombret, H., Orvain, C., Giltat, A., Recher, C., Ifrah, N., Guardiola, P., Hunault-Berger, M., & Abbara, C.
(2022). Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. Pharmaceutics, 14(4), 792.
https://doi.org/10.3390/pharmaceutics14040792
